REGENXBIO (NASDAQ:RGNX) Upgraded at Mizuho

Mizuho upgraded shares of REGENXBIO (NASDAQ:RGNX) to a strong-buy rating in a research note released on Monday,Zacks reports.

Several other analysts also recently issued reports on the company. Morgan Stanley reiterated an “overweight” rating and set a $18.00 price target on shares of REGENXBIO in a research note on Friday, August 7th. HC Wainwright reissued a “buy” rating on shares of REGENXBIO in a research note on Monday, September 28th. Robert W. Baird reduced their target price on REGENXBIO from $32.00 to $29.00 and set an “outperform” rating for the company in a report on Tuesday, August 25th. Leerink Partners increased their price target on REGENXBIO from $17.00 to $18.00 and gave the company an “outperform” rating in a report on Monday, June 22nd. Finally, Zacks Research raised shares of REGENXBIO from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 12th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, REGENXBIO presently has an average rating of “Moderate Buy” and a consensus price target of $23.17.

REGENXBIO Trading Up 1.9%

RGNX stock opened at $7.59 on Monday. The firm has a market cap of $501.02 million, a PE ratio of -2.00 and a beta of 1.13. REGENXBIO has a 1 year low of $5.45 and a 1 year high of $16.19. The company has a fifty day simple moving average of $9.14 and a 200 day simple moving average of $9.10.

REGENXBIO (NASDAQ:RGNX) last posted its earnings results on Thursday, August 6th. The biotechnology company reported $0.43 EPS for the quarter, topping the consensus estimate of $0.08 by $0.35. REGENXBIO had a negative net margin of 112.58% and a negative return on equity of 220.07%. The firm had revenue of $108.02 million for the quarter, compared to the consensus estimate of $97.63 million. As a group, analysts forecast that REGENXBIO will post -3.91 EPS for the current fiscal year.

Institutional Trading of REGENXBIO

Hedge funds have recently added to or reduced their stakes in the business. Versant Capital Management Inc raised its position in REGENXBIO by 60.4% in the 2nd quarter. Versant Capital Management Inc now owns 2,741 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 1,032 shares during the last quarter. Diversified Trust Co grew its holdings in shares of REGENXBIO by 15.9% during the first quarter. Diversified Trust Co now owns 15,499 shares of the biotechnology company’s stock worth $130,000 after purchasing an additional 2,121 shares during the last quarter. Quantbot Technologies LP bought a new stake in shares of REGENXBIO during the second quarter worth $51,000. Legal & General Group Plc acquired a new stake in shares of REGENXBIO in the second quarter valued at $56,000. Finally, Entropy Technologies LP bought a new position in shares of REGENXBIO in the first quarter valued at about $87,000. Institutional investors own 88.08% of the company’s stock.

REGENXBIO Company Profile

REGENXBIO Inc is a biotechnology company focused on developing and commercializing gene therapies for serious diseases. The company’s programs are based primarily on its proprietary NAV AAV Technology Platform, which uses adeno-associated virus (AAV) vectors to deliver genetic material to targeted cells. Its research has emphasized conditions affecting the central nervous system, muscles and other tissues.

REGENXBIO’s pipeline has included investigational therapies such as RGX-121 for mucopolysaccharidosis type II, RGX-111 for mucopolysaccharidosis type I and RGX-202 for Duchenne muscular dystrophy.